NT_1170x120_1-11-18

Incyte Corp.

FDA recommends the approval of Baricitinib 2mg

FDA recommends the approval of Baricitinib 2mg

INDIANAPOLIS — Eli Lilly and Incyte Corp.  announced that the U.S. Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the